GLP-1 clinical trials in Minnesota: 17 recruiting now

17 GLP-1 clinical trials are recruiting at 22 sites in 5 cities across Minnesota. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Minnesota

1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

   Phase 4. Brigham and Women's Hospital plans to enroll 6,000 participants.

   A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

   Who can join. Adults 40 to 80, have type 2 diabetes.

   2 sites in Minnesota

   • Essentia Health, Duluth. 218-576-0480
   • University of Minnesota, Minneapolis. 612-301-3105

   NCT05390892 on ClinicalTrials.gov. See whether you qualify.

2. Fibrosis Lessens After Metabolic Surgery

   Phase 4. The Cleveland Clinic plans to enroll 120 participants.

   A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people reduce liver fat.

   Who can join. Adults 18 to 75, have fatty liver disease (MASLD) with liver scarring (fibrosis), BMI 35+.

   1 site in Minnesota

   • Mayo Clinic, Rochester

   NCT06374875 on ClinicalTrials.gov. See whether you qualify.

3. Tirzepatide in PWS, HO and GNSO

   Phase 4. Grace Kim plans to enroll 36 participants.

   A study testing whether a GLP-1 and GIP medicine, tirzepatide, can help people with Prader-Willi syndrome lose weight.

   Who can join. Adults 18 to 26, have Prader-Willi syndrome, BMI 30+.

   1 site in Minnesota

   • Children's Minnesota, Saint Paul. 651-220-5730

   NCT06901245 on ClinicalTrials.gov. See whether you qualify.

4. Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder

   Phase 4. Mayo Clinic plans to enroll 100 participants.

   A study testing whether a GLP-1 medicine, semaglutide, can help people with bipolar I disorder lose weight.

   Who can join. Adults 18 to 65, have bipolar I disorder, BMI 27+.

   1 site in Minnesota

   • Mayo Clinic, Rochester. 507-255-9352

   NCT07213466 on ClinicalTrials.gov. See whether you qualify.

5. A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity

   Phase 4. Gila Therapeutics, Inc plans to enroll 40 participants.

   A study testing whether a GLP-1 medicine, semaglutide, can help people lose weight.

   Who can join. Adults 18 to 65, have obesity or are overweight, BMI 30+.

   1 site in Minnesota

   • Clinical Research Institute of Minnesota, Minneapolis. 612-333-2200

   NCT07728383 on ClinicalTrials.gov. See whether you qualify.

6. A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)

   Phase 3. Eli Lilly and Company plans to enroll 125 participants.

   A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people lose weight.

   Who can join. Children and teens 6 to 17, have obesity.

   3 sites in Minnesota

   • University of Minnesota Masonic Children's Hospital, Minneapolis
   • Mayo Clinic - PIN, Rochester
   • Children's Minnesota Pediatric Endocrinology Clinic & McNeeley Diabetes Center, Saint Paul

   NCT06672549 on ClinicalTrials.gov. See whether you qualify.

7. A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight

   Phase 3. Novo Nordisk A/S plans to enroll 460 participants.

   A study testing whether a study medicine from Novo Nordisk, cagrilintide, can help people lose weight.

   Who can join. Children and teens 8 to 18, are overweight.

   2 sites in Minnesota

   • University of Minnesota, Minneapolis
   • Synexus Clinical Research US-MN, Richfield

   NCT07253285 on ClinicalTrials.gov. See whether you qualify.

8. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

   Phase 3. Novo Nordisk A/S plans to enroll 2,500 participants.

   A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

   Who can join. Adults 18+, have obesity, BMI 35+.

   2 sites in Minnesota

   • International Diabetes Center, Minneapolis
   • AES Minneapolis DRS, Richfield

   NCT07564414 on ClinicalTrials.gov. See whether you qualify.

9. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

   Phase 3. Boehringer Ingelheim plans to enroll 1,800 participants.

   A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

   1 site in Minnesota

   • MNGI Digestive Health, PA, Minneapolis. 833-602-2368

   NCT06632444 on ClinicalTrials.gov. See whether you qualify.

10. LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

    Phase 3. Boehringer Ingelheim plans to enroll 1,590 participants.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

    Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH), BMI 25+.

    1 site in Minnesota

    • MNGI Digestive Health, PA, Minneapolis. 833-602-2368

    NCT06632457 on ClinicalTrials.gov. See whether you qualify.

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

Written and edited by John SamarasAbout this siteContact